ConductScience.org, home

Paper3497883

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.

Brunda MJ and 2 others. Int J Cancer, 1987. Cited by 155 papers, by iCite.

Cite this record

ConductScience Library. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Papers, record 3497883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3497883

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.
PubMed
Journal
Int J Cancer
PubMed
Year
1987
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
155
iCite
Relative citation ratio, by iCite
5.48
iCite
Revised in PubMed
2019-07-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brunda MJM J
2Bellantoni DD
3Sulich VV

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interferon Type IMajor topic
Interleukin-2Major topic
Killer Cells, NaturalMajor topic
Neoplasms, ExperimentalMajor topic
Animals
Female
Mice
Mice, Inbred C57BL
Neoplasm Metastasis
Recombinant Proteins

Source PubMed

Download CSV of topics

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 155 citations.

PMIDTitleJournalYearIn PapersSource
27313471Anti-colorectal cancer effect of interleukin-2 and interferon-β fusion gene driven by carcinoembryonic antigen promoter.Onco Targets Ther2016https://conductscience.org/library/papers/27313471PubMed
12622456Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.J Neurooncol2003https://conductscience.org/library/papers/12622456PubMed
11917944Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.Med Oncol2001https://conductscience.org/library/papers/11917944PubMed
11114704Alleviating oxidative stress in cancer immunotherapy: a role for histamine?Med Oncol2000https://conductscience.org/library/papers/11114704PubMed
10411104Effects of immunization with tumor cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastasis of colon26 cells in BALB/c mice.Clin Exp Metastasis1999https://conductscience.org/library/papers/10411104PubMed
8299113Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.Cancer Immunol Immunother1994https://conductscience.org/library/papers/8299113PubMed
8242661Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8242661PubMed
8104230Antitumor and antimetastatic activity of interleukin 12 against murine tumors.J Exp Med1993https://conductscience.org/library/papers/8104230PubMed
8001030Histamine in immunotherapy of advanced melanoma: a pilot study.Cancer Immunol Immunother1994https://conductscience.org/library/papers/8001030PubMed
7923989Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2.Clin Exp Metastasis1994https://conductscience.org/library/papers/7923989PubMed
7852191Synergistic antimetastatic effects of lentinan and interleukin 2 with pre- and post-operative treatments.Jpn J Cancer Res1994https://conductscience.org/library/papers/7852191PubMed
7779731Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.Br J Cancer1995https://conductscience.org/library/papers/7779731PubMed
7678979Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.Br J Cancer1993https://conductscience.org/library/papers/7678979PubMed
2786729Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.Br J Cancer1989https://conductscience.org/library/papers/2786729PubMed
2785852Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2785852PubMed
2598180Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2598180PubMed
2513305Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.Jpn J Cancer Res1989https://conductscience.org/library/papers/2513305PubMed
2503476Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.Jpn J Cancer Res1989https://conductscience.org/library/papers/2503476PubMed
2495179Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2495179PubMed
2407894Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.Klin Wochenschr1990https://conductscience.org/library/papers/2407894PubMed

See all 28 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3497883

GET https://conductscience.org/api/papers/v1/3497883/cited_by?page=2